Nirsevimab (Beyfortus®), a long-acting intramuscular recombinant neutralising human
IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus …

Bronchiolitis is an acute respiratory illness that is the leading cause of hospitalization in
young children. This document aims to update the consensus document published in 2014 …

Background Whether vaccination during pregnancy could reduce the burden of respiratory
syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is …

Background Vaccination against respiratory syncytial virus (RSV) during pregnancy may
protect infants from RSV disease. Efficacy and safety data on a candidate RSV prefusion F …

In May 2023, the US FDA advisors endorsed Pfizer's pregnancy-administered vaccine
(branded ABRYSVO) to protect infants from respiratory syncytial virus (RSV) infection …

Monoclonal antibodies (mABs) are safe and effective proteins produced in laboratory that
may be used to target a single epitope of a highly conserved protein of a virus or a bacterial …

Objective Decision trees are efficient and reliable decision‐making algorithms, and
medicine has reached its peak of interest in these methods during the current pandemic …

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection
among infants and young children, resulting in annual epidemics worldwide. Since the …

Intercellular contacts between epithelial cells are established and maintained by the apical
junctional complexes (AJCs). AJCs conserve cell polarity and build epithelial barriers to …

The respiratory syncytial virus (RSV) causes a substantial burden worldwide. After over six
decades of research, there is finally a licensed immunization option that can protect the …